scispace - formally typeset
Open AccessJournal Article

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

Reads0
Chats0
TLDR
Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.
About
This article is published in The Lancet.The article was published on 1998-09-12 and is currently open access. It has received 7395 citations till now. The article focuses on the topics: Metformin & Type 2 diabetes.

read more

Citations
More filters
Journal ArticleDOI

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

TL;DR: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up.
Journal ArticleDOI

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.

TL;DR: A unified working diagnostic tool for the metabolic syndrome that is convenient to use in clinical practice and that can be used world-wide so that data from different countries can be compared.
References
More filters
Journal Article

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 - 
TL;DR: In this article, the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal Article

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease

TL;DR: Sulfonylurea, metformin, and insulin therapies were similarly effective in improving glucose control compared with a policy of diet therapy and whether any specific therapy is advantageous or disadvantageous.
Journal ArticleDOI

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

TL;DR: The ability of troglitazone to reduce insulin resistance and improves glucose tolerance in obese subjects with either impaired or normal glucose tolerance could be useful in preventing NIDDM.
Journal ArticleDOI

Biguanides and NIDDM

TL;DR: Because metformin does not cause clinical hypoglycemia, it is actually an antihyperglycemic drug that helps combat hypertriglyceridemia, and it has been ascribed some vasoprotective properties.
Journal ArticleDOI

UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.

TL;DR: The UK Prospective Diabetes Study is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality.
Related Papers (5)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 -